Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

The Impact of Concomitant Metabolic Syndrome in Patients with Schizophrenia on Clinical Dynamics and Social Adaptationющим метаболическим синдромом

V.V. Dubrovskaya 1, E.G. Kornetova1,2, A.V. Semke 1,2, S.A. Ivanovа 1, M.B. Arzhanik 2, N.E. Golovakha 2

1 Mental Health Research Institute Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
2 Federal State Budgetary Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation, Novosibirsk, Russia

Purpose: Studing the effect of metabolic disorders on the dynamics of schizophrenia and the development of social changes in patients with schizophrenia with concomitant MS.
Materials and methods. The study included 150 patients with schizophrenia with a verified diagnosis of schizophrenia according to ICD-10, undergoing inpatient treatment at the clinic of the Mental Health Research Institute. All patients receive basic therapy using conventional and atypical antipsychotic drugs at recommended therapeutic doses for 6 weeks. Measurements of morbidity, blood pressure and biochemical indicators were used to reliably diagnose IDF metabolic syndromes. Patients' adaptive capacities are assessed using the social adaptation self-assessment scale (SSAS). The scale of positive and negative syndromes (PANSS) was used to assess the clinical manifestations of schizophrenia.
Results. According to the results of the assessment of social adaptation, it was revealed that there were no differences between the subgroups of patients. According to the results of psychometric assessment of the dynamics of clinical symptoms in patients with schizophrenia and the accompanying metabolic syndrome, lower rates of reduction of positive and negative symptoms in the process of antipsychotic therapy were revealed.
Conclusion. Metabolic syndrome is a complex of concomitant somatic disorders that aggravate the clinical manifestations of schizophrenia and adversely affect the effectiveness of psychopharmacotherapy. Probably, the presence of metabolic syndrome does not adversely affect the level of social adaptation of patients.

Contact information: Vika.dubrovskaya.vd@gmail.com

References: 

1. Gurovich I.Ya., Shmukler A.B., Zajceva Yu.S. Nejrokognitivny`j deficit u bol`ny`x shizofreniej // Nevrologiya, nejropsixiatriya, psixosomatika. – 2012. – № 2. – S. 75–78.

2. Salimi K., Jarskog L.F., Lieberman J.A. Antipsychotic drugs for first-episode schizophrenia: a comparative review // CNS Drugs. – 2009. – Oct. 23. – № 10. – P. 837–892.

3. Mosolov S.N., Czukarzi E`.E`., Kapiletti S.G. Antipsixoticheskaya farmakoterapiya shizofrenii: ot nauchny`x danny`x k klinicheskim rekomendaciyam // Biologicheskie metody` terapii psixicheskix rasstrojstv. – M.: Social`no-politicheskaya my`sl`, 2012. – S. 11–61.

4. Vancampfort D. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis // World Psychiatry. – 2015. – 14 (3). – P. 339–347.

5. Mosolov S.N., Ry`vkin P.V., Serditov O.V., Lady`zhenskij M.Ya., Potapov A.V. Metabolicheskie pobochny`e e`ffekty` sovremennoj antipsixoticheskoj farmakoterapii // Social`naya i klinicheskaya psixiatriya. – 2008. – T. 18, № 3. – S. 75–90.

6. Alfimov P.V., Ry`vkin P.V., Lady`zhenskij M.Ya., Mosolov S.N. Metabolicheskij sindrom u bol`ny`x shizofreniej (obzor literatury`) // Sovremennaya terapiya psixicheskix rasstrojstv. – 2014. – № 3. – S. 8–14.

7. Samson S.L., Garber A.J. Metabolic syndrome // Endocrinol Metab Clin North Am. – 2014. – Mar. – Vol. 43 (1). – P. 1–23.

8. Marty`nixin I.A. Metabolicheskij sindrom u bol`ny`x shizofreniej: rasprostranennost`, faktory` riska, mery` profilaktiki. Diss. … kand. med. nauk. – Sankt–Peterburg, 2009.

9. Enez Darcin A., Yalcin Cavus S., Dilbaz N. et al. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings // Schizophr Res. – 2015. – Vol. 166, No. 1–3. – P. 201–206.

10. Tek Cz., Kuczukgonczu S., Guloksuz S., Vudks S.V., Srixari V.X., Annamalaj A. Inducirovannaya antipsixotikami pribavka v vese u pacientov s pervy`m psixoticheskim e`pizodom: meta-analiz // Social`naya i klinicheskaya psixiatriya. – 2016. – T. 26, № 1. – C.45–48.

11. Bellavia A., Centorrino F., Jackson J.W., Fitzmaurice G., Valeri L. The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial // Schizophr Res. – 2018. – Dec. 21. – DOI: 10.1016/j.schres.2018.12.006

12. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study // Clinical practice and epidemiology in mental health: CP & EMH. – 2006. – Vol. 2 (1). – P. 14.

13. Koponen H.J., Hakko H.H., Saari K.M., Lindeman S.M., Karvonen K.M., Isohanni M.K., Lauren L.H., Savolainen M.J., Järvelin M.R. The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study // World J Biol Psychiatry. – 2010. – Vol. 11, No. 2. – P. 262–267.

14. Raben A.T., Marshe V.S., Chintoh A., Gorbovskaya I., Müller D.J., Hahn M.K. The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. Front Neurosci. – 2018. –Jan 22. – Vol. 11. – P. 741.

15. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006. – URL: https://idf.org/metabolic_syndrome, website of the International Diabetes Federation (accessed 07.08.2018).

16. Kay S.R., Opler L.A., Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia // Schizophr Bull. – 1987. – Vol. 13. – P. 261–276.

17. Mosolov S.N. Shkaly` psixometricheskoj ocenki simptomatiki shizofrenii i koncepciya pozitivny`x i negativny`x rasstrojstv. – M.: Novy`j czvet, 2001. – 238 s.

18. Bosc M., Dubini A., Polin V. The Social Adaptation Self-Evaluation Scale (SASS). European Neuropsychopharmacology. – 1997. – Vol. 7 (1). – P. 57–70.

19. Popp B.S., Manea M.M., Moraru M.O. Treatment adherence and social functioning in patients diagnosed with schizophrenia and treated with antipsychotic depot medication // Clujul Medical. – 2014. – Vol. 87 (2). – P. 109–121.

20. Marusin A.V., Kornetov A.N., Svarovskaya M.G., Vagajceva K.V., Pavlenyuk E.S., Stepanov V.A. Associaciya genov podverzhennosti k alkogolizmu, shizofrenii i bolezni Al`czgejmera s psixodiagnosticheskimi priznakami v populyacii russkix // Byulleten` sibirskoj mediciny`. – 2016. – T. 15, № 5. – C. 83–96.

21. Rebrova O.Yu. Statisticheskij analiz medicinskix danny`x: Primenenie paketa prikladny`x programm STATISTICA. – M.: MediaSfera, 2006. 129 c.

22. Tokareva Z.N., Mamedov M.N., Deev A.D., Evdokimova A.A., Oganov R.G. Rasprostranennost` i osobennosti proyavlenij metabolicheskogo sindroma vo vzrosloj gorodskoj populyacii // Kardiovaskulyarnaya terapiya i profilaktika. – 2010. – T. 9, № 1. – S. 4–9.

23. Kajdashev I. P. E`volyuciya ponyatiya «metabolicheskij sindrom» i ego sovremennoe znachenie. // Nauchny`e diskussii. – 2012. – № 2 (88). – S. 157–160.